A recently developed model using malignancy-specific neoantigens appears to predict tumor response to ICI therapy in patients with melanoma and lung cancer receiving anti-CTLA-4 and anti-PD-1 therapy, respectively [152]. The gene discussed is CTLA4; the disease is neoplasm.